Click here for Sutent® (sunitinib malate) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
Experience that stands the test of time
SUTENT (sunitinib malate) is indicated for the treatment of advanced and/or metastatic renal cell carcinoma (mRCC) in adults.1
Dosing and monitoring requirements for SUTENT
Patient subgroups and clinical efficacy.
Important safety information and safety outcomes
An introductory video to SUTENT (sunitinib malate) Mode of Action
SUTENT (sunitinib malate) resources to support your patients including a treatment information leaflet and dosing cards
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020